Glecaprevir/pibrentasvir demonstrates high SVR rates in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis following an 8-week treatment duration (SURVEYOR-II, Part 4)

Authors
Category Primary study
JournalHepatology
Year 2016
This article has no abstract
Epistemonikos ID: f8bf6c59185d808af8cb973d3efc00bd35394bdd
First added on: Feb 08, 2025